News > Revised guidelines for do’s and dont’s for COVID-19 therapy

Revised guidelines for do’s and dont’s for COVID-19 therapy

The revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to severe" disease and those with no renal or hepatic dysfunction within 10 days of the onset of any symptom.

EUA or off-label use of the tocilizumab drug may be considered for use in the presence of severe disease, preferably within 24 to 48 hours of onset of severe disease or ICU admission.